PolyPid enrolls last patient for planned unblinded interim analysis in SHIELD II

PolyPid has enrolled the last patient required in order to conduct the planned unblinded interim analysis in its ongoing SHIELD II Phase 3 trial for D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery with large incisions. The unblinded interim analysis will be conducted during the current quarter, following the completion of the 30-day follow-up assessment for the last patient. The unblinded interim analysis may allow for early trial conclusion due to positive efficacy, continuation to planned patient recruitment, sample size re-assessment, or futility. Approximately 430 subjects have been enrolled to date in the SHIELD II Phase 3 trial.